

Remarks

The undersigned agent thanks the Examiner for the time and courtesy extended in our February 24, 2003 telephone interview. In that interview, we discussed descriptions contained in the specification of the construction of vectors of claims 13, 15 and 18, and whether those descriptions were sufficient to enable one of skill in the art to reproduce the claimed vectors from commercially available starting materials. We also discussed whether a biological deposit of any of the claimed vectors would be appropriate and/or necessary. Although we were able to reach agreement that the originally filed application was enabling for the vectors of claims 15 and 18, no agreement was reached as to the vector of claim 13.

As a result of the foregoing amendments, formal drawings have been submitted and the specification has been amended to reflect the formal drawings and to included reference to the ATCC Biological Deposit of the vector pTransSacB, claimed in claim 13.

The formal drawings are identical in content to the informal drawings originally filed in this application, but have been redrawn to correct all of the informalities indicated on the "Notice of Draftsperson's Patent Drawing Review". In order to meet the Draftsperson's requirements, originally filed Figure 8 was split up into Figures 8A and 8B. The specification has been amended to reflect this change.


Furthermore, the specification has been amended to reflect that the vector pTransSacB has been deposited with the ATCC, receiving the accession number PTA-5105. A copy of the ATCC receipt and viability statement is attached. The final Office Action states on page 4 that a deposit of this vector would overcome the only rejection remaining in this case, that of claim 13 for lack of enablement under 35 U.S.C. 112.

No new matter has been entered by these amendments and it is proper to enter the amendments after a final office action, because each responds to a requirement of the Examiner or Draftsperson and together they place the application in condition for allowance.

Since pending claims 15 and 18 are allowed in the Final Office Action and the rejection of pending claim 13 has been overcome by following the Examiner's suggestion to deposit the claimed

vector pTransSacB, this application is in condition for allowance. A prompt Notice of Allowance is respectfully requested.

Respectfully submitted,



F. Aaron Dubberley, Reg. No. 41,001
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-3737
Telefax: 908-231-2626

Docket No. USHMR2050 US NP